Amyloid Nurse Specialist - Inherited Cardiac Conditions | Mid and South Essex NHS Foundation Trust
| Posting date: | 13 November 2025 |
|---|---|
| Salary: | Not specified |
| Additional salary information: | £38,682 Per Annum (Pro Rata for Part Time) |
| Hours: | Part time |
| Closing date: | 13 December 2025 |
| Location: | Basildon, SS15 6NL |
| Company: | Southend University Hospital NHS Trust |
| Job type: | Contract |
| Job reference: | 7476283/390-CAR-BA-2253 |
Summary
We are looking for an experienced and motivated Specialist Nurse to join our Inherited Cardiac Conditions (ICC) team as a Clinical Nurse Specialist (CNS). In this role, you will work closely with the Clinical Lead and other members of the multidisciplinary team (MDT) to deliver high-quality, patient-centred care.
As part of the ICC service, you will provide expert advice, information, and support to patients and their families who are affected by, or at risk of inherited cardiac conditions — including cardiomyopathies, inherited arrhythmias, and aortopathies.
You will work autonomously within the cardiac team, managing your own caseload and ensuring care is delivered in line with best practice, national guidelines, and Trust policies.
In addition to direct patient care, you will act as a key resource for other healthcare professionals across MSE.
The primary role for the postholder will be a cardiac amyloidosis screening project. Cardiac amyloidosis of transthyretin subtype (ATTR) is an important yet underdiagnosed cause of heart failure. Robust investigation to differentiate ATTR from other causes of heart failure is crucial to guide prognostic heart failure therapies, and it is important to rule out the more aggressive AL subtype needing chemotherapy treatment promptly (median survival 6-12 months versus 5-7 years in ATTR patients). The management of ATTR cardiomyopathy has been challenging to date, limited to generic heart failure therapies without proof of prognostic benefit, and often causing severe and debilitating side effects. We are in an era of novel and targeted therapies for ATTR amyloidosis, so early identification is increasingly relevant. Access to new ATTR drugs outside of the clinical trial setting is very limited in the UK. However, a recent NICE guidance has recommended the use of Tafamadis, based on data derived from the ATTR-ACT trial confirming a statistically significant prognostic benefit of the TTR stabiliser in ATTR cardiomyopathy patients.
Our ambition is to deliver excellent local and specialist services, to improve the health and well being of our patients, and provide a vibrant place for staff to develop, innovate and build careers.
We aim to make the most of our skills and experiences so we can become the best we can be. As one organisation we will recruit the finest and retain more specialist staff due to more employment opportunities across our Trust.
Are you looking for an exciting Nurse Specialist role using your unique qualities? Then we want to hear from you.
For full details about this varied and rewarding role, please see attached job description.
We look forward to your application.
Please be aware that we reserve the right to close this vacancy early if we receive a suitable number of applications.
This advert closes on Thursday 27 Nov 2025